Peer-influenced content. Sources you trust. No registration required. This is HCN.

The Epoch TimesPeople with More COVID-19 Vaccine Doses More Likely to Contract COVID-19: Study

Increased COVID-19 Risk Linked to Higher Vaccine Doses: Implications for Vaccine Strategy and Immune Response Dynamics

A recent study conducted by Cleveland Clinic researchers has revealed a surprising trend: individuals who have received multiple COVID-19 vaccine doses are more likely to contract the virus than those with fewer or no doses. This analysis, which focused on the clinic’s employees, suggests a complex interaction between vaccine-induced immunity and susceptibility to COVID-19, challenging existing assumptions about the long-term effectiveness of repeated vaccinations.

Key Points:

  • Study Overview: Researchers at Cleveland Clinic observed that employees who received two or more COVID-19 vaccine doses had a higher incidence of contracting the virus compared to those with zero or one dose.
  • Risk Assessment: The risk increased with the number of doses: 1.5 times higher for two doses, 1.95 times for three doses, and 2.5 times for more than three doses.
  • Study Findings: Even after adjusting for multiple variables, the elevated risk of COVID-19 remained significant among the vaccinated group.
  • Possible Explanations: The study suggests that vaccine-induced immunity might be less durable and weaker than natural immunity, potentially leading to increased susceptibility over time.
  • External Opinions: Experts like Dr. Robert Malone and Dr. Harvey Risch commented on the findings, discussing potential mechanisms such as antibody-dependent enhancement and original antigenic sin, which could explain the increased risk.
  • CDC Stance: Despite these findings, the CDC continues to recommend COVID-19 vaccination for everyone aged 6 months and older. They are planning to review vaccine formulations to potentially enhance protection.
  • Effectiveness of Recent Vaccines: Another part of the study analyzed the effectiveness of the monovalent vaccine targeting the XBB.1.5 variant, showing 49% effectiveness initially, which declined over time.
  • Vaccine Response to New Strains: The researchers highlighted that immune responses trained on older virus strains might compromise protection against newer variants.
  • Clinical Implications: The findings could influence future vaccine strategies, particularly concerning the frequency and type of doses administered to the public.

“The exact reason for this finding is not clear. It is possible that this may be related to the fact that vaccine-induced immunity is weaker and less durable than natural immunity.”

More on Vaccines/Immunizations

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form